Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy
March 13, 2023
Calliditas’ Kinpeygo Receive EC's Marketing Authorization for the Treatment of Primary Immunoglobulin A Nephropathy
July 18, 2022
Calliditas Reports First Patient Randomization in P-IIb/III (TRANSFORM) Study for Primary Biliary Cholangitis
February 15, 2022
Calliditas’s Tarpeyo (budesonide) Receives the US FDA’s Accelerated Approval for the Treatment of IgA Nephropathy
December 15, 2021
PharmaShots Weekly Snapshots (August 09, 13, 2021)
August 13, 2021
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.